Negative serum pregnancy test within 30 days prior to registration for females of childbearing potential.
Negative pregnancy test of females with childbearing potential.
Females of childbearing potential must have a negative serum pregnancy test
For all females of childbearing potential, a negative serum pregnancy test must be obtained within 3 days prior to starting study treatment
A negative pregnancy test (for females of childbearing potential)
Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential)
Have a negative pregnancy test result at Screening for females of childbearing potential
Negative pregnancy test for females of childbearing potential
Females of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to start of first cycle of therapy
Serum or urine pregnancy test (for females of childbearing potential) negative ?7 days of starting treatment
Have a negative pregnancy test result at Screening for females of childbearing potential
Negative urine or serum pregnancy test for females of childbearing potential
Negative serum pregnancy test at the time of enrollment for females of childbearing potential
Serum/urine pregnancy test (for females of childbearing potential) that is negative within 72 hours prior to initiation of first dose of treatment (a patient is of childbearing potential if, in the opinion of the investigator, she is biologically capable of having children and is sexually active)
Negative serum pregnancy test at the time of enrollment for females of childbearing potential
Females of childbearing potential must have a negative pregnancy test within 21 days prior to Study Day 0.
Serum or urine pregnancy test (for females of childbearing potential) negative at screening and at the baseline visit (before the patient may receive the investigational product)
Pregnant females are excluded; females of childbearing age/menstruating must confirm that either they are not sexually active or have a negative pregnancy test prior to initiation of radiation therapy
For females of childbearing potential, a negative urine pregnancy test must be documented prior to randomization.
Females of childbearing potential must have a negative urine or serum pregnancy test within 1 week prior to the start of treatment
Females of childbearing potential must have a negative serum or urine pregnancy test (females who have undergone surgical sterilization or who have been postmenopausal for at least 2 years are not considered to be of childbearing potential)
Females of childbearing potential must have a negative pregnancy test within 30 days prior to randomization. Females who are postmenopausal for at least 1 year (defined as more than 12 months since last menses) or are surgically sterilized do not require this test.
Females of childbearing potential must have a negative pregnancy test within 30 days prior to enrollment. Females who are postmenopausal for at least 1 year (defined as more than 12 months since last menses) or are surgically sterilized do not require this test.
Females of childbearing potential must have negative results for pregnancy test performed:
Not pregnant - females of childbearing potential must have a negative pregnancy test within 7 days of apheresis
DONOR: Not pregnant - females of childbearing potential must have a negative pregnancy test within 7 days of apheresis
Serum/urine pregnancy test (for females of childbearing potential) that is negative at screening and immediately prior to initiation of treatment (first dose).
Serum pregnancy test (for females of childbearing potential) negative at screening
Females with childbearing potential must have had a negative urine or serum pregnancy test =< 7 days before the first dose of deferasirox and must also not be breastfeeding
Negative pregnancy test in females of reproductive age
Pregnant or breast feeding; females of childbearing potential must have a negative pregnancy test prior to starting therapy
Females of childbearing potential must have a negative pregnancy test and agree to use contraception during on-study protocol treatment.
Serum or urine pregnancy test (for females of childbearing potential) negative =< 7 days of registration
ENTRECTINIB EXCLUSION CRITERIA: Females of childbearing potential must have a negative serum pregnancy test during screening and must not be breastfeeding or intending to become pregnant during the study
Females of childbearing potential must have negative serum or urine pregnancy test.
Females with childbearing potential must have a negative serum pregnancy test within 14 days prior to treatment start
For all females of childbearing potential, a negative pregnancy test must be obtained within 3 days before starting study treatment
For females of childbearing potential, a negative serum pregnancy test must be documented within 72 hours of receiving the first dose of vorinostat
DONOR: Pregnant females\r\n* NOTE: a serum or urine pregnancy test for females of reproductive potential must be conducted within 7 days prior to initiation of recipientâ€™s conditioning regimen
Females of childbearing potential must have a negative urine pregnancy test at screening and be willing to have additional urine pregnancy tests during the study; females considered not of childbearing potential include those who have been in menopause at least 2 years, or had tubal ligation at least 1 year prior to screening, or who have had total hysterectomy
Females of childbearing potential must have a negative pregnancy test within 1 week prior to treatment with 131I-MIBG
Females of childbearing potential must not be pregnant; this will be confirmed by a negative serum pregnancy test within 14 days prior to starting study treatment
Negative serum test to rule out pregnancy within 2 weeks prior to registration in females of childbearing potential (non-childbearing potential defined as premenarchal, greater than one year post-menopausal, or surgically sterilized)
Females of childbearing potential must have a negative serum ?-Hcg pregnancy test result within 7 days of first study dose. Female patients who are surgically sterilized or who are > 45 years old and have not experienced menses for > 2 years may have ?- Hcg pregnancy test waived.
For females of childbearing potential, a negative pregnancy test must be documented prior to randomization
Females of childbearing potential must have negative serum or urine pregnancy test within 7 days prior to study entry; the effects of lapatinib on the developing human fetus are unknown; however, bevacizumab is known to be teratogenic and detrimental to fetal development and endometrial proliferation, thereby having a negative effect on fertility
Pregnant or breastfeeding; females of childbearing potential must have a negative pregnancy test prior to starting therapy
For females, a negative pregnancy test
Negative serum or urine pregnancy test (females of childbearing potential only).
DONORS: Not pregnant - females of childbearing potential must have a negative pregnancy test within 7 days of mobilization start
Females of childbearing potential must have a negative serum pregnancy test at screening
Females of childbearing potential must have a negative pregnancy test within 7 days of being registered for protocol therapy
Pregnant females are excluded from this study; all females of child-bearing potential will undergo a serum pregnancy test within 48 hours prior to FBnTP administration
Negative pregnancy test for females of childbearing potential
Females of childbearing potential that do not have a negative pregnancy test.
Negative Serum pregnancy test for females of childbearing potential
A negative pregnancy test (for females of childbearing potential).
Females with childbearing potential: Have had a negative serum pregnancy test ?7 days before the first dose of study drug and also must not be breastfeeding.
Females of childbearing potential must have a negative serum pregnancy test
Females of childbearing potential have a negative serum pregnancy test (preceding 72 hours of first day of BBI608 treatment).
Females of childbearing potential must have a negative serum or urine pregnancy test prior to patient registration
Negative serum pregnancy test in females of childbearing potential
Negative pregnancy test for females of childbearing potential
Females of childbearing potential must have a negative serum pregnancy test
Negative pregnancy test for females of childbearing potential
For females of childbearing potential, must have a negative pregnancy test
Females of childbearing potential must have a negative serum pregnancy test within 14 days of treatment
Females of childbearing potential must have a negative pregnancy test within 30 days prior to randomization. Females who are postmenopausal for at least 1 year (defined as more than 12 months since last menses) or are surgically sterilized do not require this test.
Females of childbearing potential must have a negative urine or serum pregnancy test within one week prior to start of treatment.
Pregnant as determined by a positive serum pregnancy test within 14 days prior to registration on study (for females of childbearing potential)
Females of childbearing potential must have a negative serum or urine pregnancy test at screening
Females of childbearing potential should have a negative pregnancy test
Females of childbearing potential have a negative serum pregnancy test.
Negative urine or serum pregnancy test for females of childbearing potential
Females who are breastfeeding or pregnant. For females of childbearing potential, a negative screening pregnancy test must be obtained within 72 hours before the first dose of study drug
For females with reproductive potential: a negative serum pregnancy test
Females of childbearing potential must have a negative serum pregnancy test
Females of childbearing potential must have a negative serum pregnancy test.
Females of childbearing potential must have a negative serum pregnancy test performed within 7 days prior to the start of treatment
Negative pregnancy test in females of reproductive age
Females of childbearing potential must have a negative pregnancy test within 7 days of being registered for protocol therapy
Females with childbearing potential must have had a negative serum pregnancy test less than or equal to 7 days prior to the first dose of study drug
Females of childbearing potential must have a negative pregnancy test (by serum beta-HCG) within 7 days prior to the start of treatment.
Serum/urine pregnancy test (for females of childbearing potential) negative at screening and before the patient will receive the study treatment.
Females of childbearing potential must undergo pregnancy testing based on the frequency outlined in Pregnancy Prevention Risk Minimization Plan and pregnancy results must be negative.
Negative serum pregnancy test in females of childbearing potential
Negative serum pregnancy test for females
Females of childbearing potential must have a negative pregnancy test at screening; patients taking oral contraceptives should use an additional method of contraception
Negative pregnancy test for Females of childbearing potential.
Females of childbearing potential must have a negative pregnancy test result within 7 days prior to the first dose of study drug.
Females of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to start of ipilimumab
Females of childbearing potential must have a negative serum pregnancy test
Females (childbearing potential): Have had a negative serum pregnancy test before the first dose of study drug and not be breast-feeding.
Females with reproductive potential: Must have a negative serum or urine pregnancy test within 7 days prior to the first dose of any study drug.
Females of childbearing potential must have a negative pregnancy test within 7 days prior to registration for protocol therapy.
Females must be surgically or biologically sterile or postmenopausal (amenorrheic for at least 12 months) or if of childbearing potential, must have a negative urine pregnancy test within 72 hours or serum pregnancy test within 2 weeks of signing the informed consent document
Females of childbearing potential must have a negative serum pregnancy test at screening
Females of childbearing potential have a negative pregnancy test within 72 hours prior to initiating study drug dosing
Pregnant females (women of childbearing potential must have a negative serum pregnancy test prior to enrollment)
Pregnancy or nursing: All females of childbearing age must have a negative serum or urine pregnancy test < 7 days before study drug administration
For females of childbearing potential, a negative serum pregnancy test must be documented prior to enrollment
Serum pregnancy test negative for females of childbearing potential
Females of childbearing potential must have a negative pregnancy test; sexually active patients must agree to use contraception prior to, during, and 30 days after last dose
Females of childbearing potential must not be pregnant or breastfeeding on admission for conditioning for SCT and a pregnancy test will be required for all females of child-bearing potential
Negative serum pregnancy test at the time of enrollment for females of childbearing potential
Negative serum pregnancy test for females of childbearing potential
Females of childbearing potential must have a negative serum pregnancy test
Negative serum pregnancy test for females of childbearing age (11- 55 years) and/or lack child-bearing potential
All females of childbearing age must have a negative pregnancy test before beginning the study
